Honduras vs Tajikistan: HIV/AIDS deaths averted by antiretroviral therapy
Honduras
839.71 deaths
in 2024
Tajikistan
827.83 deaths
in 2024
Honduras rank
78th
Tajikistan rank
79th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Honduras
- Tajikistan
How they compare
Honduras currently reports 839.71 deaths against 827.83 deaths in Tajikistan, a difference of 11.88 deaths.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Tajikistan ahead.
Honduras ranks 78th and Tajikistan ranks 79th of 157 countries.
Honduras has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Honduras | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 578.33 deaths | 10.42 deaths | 567.91 deaths | Honduras |
| 2010s | 1,022 deaths | 340.73 deaths | 681.19 deaths | Honduras |
| 2020s | 855.75 deaths | 755.08 deaths | 100.67 deaths | Honduras |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Honduras or Tajikistan?
- Honduras, at 839.71 deaths against 827.83 deaths in Tajikistan as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Honduras and Tajikistan?
- 11.88 deaths, with Honduras ahead.
- How many years of comparable data are there for Honduras and Tajikistan?
- 35 years are reported by both, from 1990 to 2024.
- How do Honduras and Tajikistan rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Honduras ranks 78th and Tajikistan ranks 79th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.